Stock Worth Watching: What’s in Prothena Corporation PLC After Today’s Significant Increase?

Stock Worth Watching: What's in Prothena Corporation PLC After Today's Significant Increase?

The stock of Prothena Corporation PLC (NASDAQ:PRTA) is a huge mover today! About 229,633 shares traded hands. Prothena Corporation PLC (NASDAQ:PRTA) has risen 72.17% since March 2, 2016 and is uptrending. It has outperformed by 63.91% the S&P500.
The move comes after 5 months positive chart setup for the $2.29 billion company. It was reported on Oct, 5 by Barchart.com. We have $102.83 PT which if reached, will make NASDAQ:PRTA worth $1.37B more.

Analysts await Prothena Corporation PLC (NASDAQ:PRTA) to report earnings on November, 7. They expect $-1.23 earnings per share, down 68.49% or $0.50 from last year’s $-0.73 per share. After $-1.18 actual earnings per share reported by Prothena Corporation PLC for the previous quarter, Wall Street now forecasts 4.24% negative EPS growth.

Prothena Corporation PLC (NASDAQ:PRTA) Ratings Coverage

Out of 4 analysts covering Prothena Corp (NASDAQ:PRTA), 4 rate it a “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. Prothena Corp has been the topic of 9 analyst reports since July 22, 2015 according to StockzIntelligence Inc. The rating was initiated by Barclays Capital with “Overweight” on Friday, May 13. Barclays Capital maintained the stock with “Overweight” rating in Thursday, August 4 report. The rating was initiated by Credit Suisse on Thursday, January 21 with “Outperform”. The rating was maintained by Wedbush on Tuesday, August 4 with “Outperform”. The rating was maintained by RBC Capital Markets with “Outperform” on Thursday, November 19. The firm earned “Outperform” rating on Friday, February 19 by Wedbush.

According to Zacks Investment Research, “Prothena Corporation plc is a biotechnology company focused on the discovery and development of therapeutic monoclonal antibodies for disease-causing proteins. The Company is developing the following programs: NEOD001 for Amyloidosis, NEOD002 for Parkinson’s disease, MCAM for Inflammatory disease and Metastatic Cancer and Tau for Alzheimer’s disease. Prothena Corporation plc is headquartered in Dublin, Ireland.”

Insitutional Activity: The institutional sentiment decreased to 1.04 in Q2 2016. Its down 0.23, from 1.27 in 2016Q1. The ratio is negative, as 13 funds sold all Prothena Corporation PLC shares owned while 40 reduced positions. 11 funds bought stakes while 44 increased positions. They now own 23.97 million shares or 13.54% less from 27.72 million shares in 2016Q1.
The Virginia-based Quantitative Invest Mngmt Limited Liability has invested 0.02% in Prothena Corporation PLC (NASDAQ:PRTA). Northern Trust reported 394,350 shares or 0% of all its holdings. Whitnell And Com has 5,487 shares for 0.06% of their US portfolio. Royal Financial Bank Of Canada accumulated 0% or 37,292 shares. Blackrock Investment Mgmt Ltd last reported 135,370 shares in the company. Bessemer Inc has 0% invested in the company for 35 shares. Proshare Ltd Liability last reported 0.01% of its portfolio in the stock. Public Employees Retirement Association Of Colorado last reported 0% of its portfolio in the stock. Invesco Ltd holds 0% of its portfolio in Prothena Corporation PLC (NASDAQ:PRTA) for 265,618 shares. Trexquant Investment Lp owns 20,419 shares or 0.09% of their US portfolio. Swiss National Bank & Trust holds 49,900 shares or 0% of its portfolio. Aqr Cap Management Limited Company has 0% invested in the company for 17,277 shares. Jennison Associate Ltd Co owns 410,117 shares or 0.02% of their US portfolio. Thrivent For Lutherans holds 0.01% or 32,100 shares in its portfolio. Cornerstone Advisors Incorporated, a Washington-based fund reported 130 shares.

Insider Transactions: Since April 13, 2016, the stock had 0 insider purchases, and 6 sales for $2.06 million net activity. Another trade for 5,000 shares valued at $225,000 was made by Selkoe Dennis J. on Monday, May 23. $162,991 worth of Prothena Corporation PLC (NASDAQ:PRTA) was sold by HOMAN ARTHUR W on Thursday, September 1. $733,204 worth of Prothena Corporation PLC (NASDAQ:PRTA) was sold by Walker Karin L.

More important recent Prothena Corporation PLC (NASDAQ:PRTA) news were published by: Twst.com which released: “Prothena Corporation plc: Prothena Announces Appointment of Dr. Gene G. Kinney …” on October 03, 2016, also Marketwatch.com published article titled: “Virtual Stock Exchange”, Fool.com published: “Why Prothena Corporation Plc is Soaring Higher Today” on March 20, 2015. More interesting news about Prothena Corporation PLC (NASDAQ:PRTA) was released by: Twst.com and their article: “Prothena Corporation plc: Prothena to Host Update on PRX003 Phase 2 …” with publication date: September 22, 2016.

PRTA Company Profile

Prothena Corporation Public Limited Company, incorporated on September 26, 2012, is a global biotechnology company. The Firm is focused on the discovery, development and commercialization of immunotherapies for the treatment of diseases that involve protein misfolding or cell adhesion. The Company’s clinical pipeline of antibody product candidates targets a range of indications, including Amyloid Light-chain (AL) amyloidosis (NEOD001), Parkinson’s disease and other related synucleinopathies (PRX002), and inflammatory diseases, including psoriasis (PRX003). The Firm has generated monoclonal antibodies that selectively bind to amyloidogenic (diseased) forms of the Transthyretin (TTR)-mediated amyloidosis (ATTR) protein. The Company’s pipeline also includes late discovery-stage programs for which the Company is testing the efficacy of antibodies in preclinical models of diseases related to amyloid or cell adhesion.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Tags: , ,

Leave a Comment